Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate
The Prostate · 2024-12 · 84 (16) · 1427-1433
DOI: 10.1002/pros.24781 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, online erschienen am 18.08.2024. Verfasst von Eric V Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Feinberg School of Medicine, Department of Urology, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Incidental Findings, Magnetic Resonance Imaging. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
To evaluate contemporary preoperative risk factors and subsequent postoperative management of incidental prostate cancer (iPCa) and incidental clinically significant prostate cancer (icsPCa, Grade Group [GG] ≥ 2 PCa).
Methods
A retrospective cohort of 811 men undergoing Holmium enucleation of the prostate (HoLEP) (January 2021–July 2022) were identified. Advanced preoperative testing was defined as prostate health index (PHI), prostate MRI, and/or negative preoperative biopsy. Descriptive statistics (Whitney‐Mann U test, Chi‐squared test) and multivariable logistic regression were performed. Results iPCa and icsPCa detection rates were 12.8% (104/811) and 4.4% (36/811), respectively. Advanced preoperative testing (406/811, 50%) was associated with younger age and higher (prostate specific antigen) PSA, prostate volume, and PSA density. On multivariable analysis, PHI ≥ 55 was associated with iPCa (OR 6.91, 95% CI 1.85‐26.3, p = 0.004), and % free PSA (%fPSA) was associated with icsPCa (OR 0.83, 95% CI 0.67, 0.94, p = 0.01). GG1 disease comprised the majority of iPCa (65%, 68/104) with median 1% involvement. iPCa patients were followed with active surveillance (median follow up 9.3 months), with higher risk patients receiving prostate MRI and confirmatory biopsy. Three patients proceeded to radical prostatectomy or radiation.
Conclusions
In the era of MRI and advanced biomarkers, the majority of iPCa following HoLEP is low volume GG1 suitable for active surveillance. A tentative follow‐up strategy is proposed. Patients with PHI ≥ 55 or low %fPSA, even with negative prostate MRI, can consider preoperative prostate biopsy before HoLEP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Feinberg School of Medicine, Department of Urology, Northwestern University, Chicago, Illinois, USA.
- Department of Urology, Ohio State University College of Medicine, Columbus, Ohio, USA.
- Feinberg School of Medicine, Department of Pathology, Northwestern University, Chicago, Illinois, USA.
ORCID-Profile: Eric V Li
Zitieren
APA
Li, E. V., Lee, M. S., Guo, J., Dean, N., Kumar, S., Mi, X., Zhou, R., Neill, C., Yang, X., Ross, A. E., & Krambeck, A. E. (2024). Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate. The Prostate, 84(16), 1427-1433. https://doi.org/10.1002/pros.24781
Vancouver
Li EV, Lee MS, Guo J, Dean N, Kumar S, Mi X, et al. Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate. The Prostate. 2024;84(16):1427-1433. doi:10.1002/pros.24781
BibTeX
@article{Li2024,
author = {Li, Eric V and Lee, Matthew S and Guo, Jenny and Dean, Nicholas and Kumar, Sai and Mi, Xinlei and Zhou, Ruoji and Neill, Clayton and Yang, Ximing and Ross, Ashley E and Krambeck, Amy E},
title = {Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate},
journal = {The Prostate},
year = {2024},
volume = {84},
number = {16},
pages = {1427--1433},
doi = {10.1002/pros.24781}
}
EUVIMED